Genetic Assessment of the Patients With Metabolic Syndrome (GENMetS)

July 20, 2011 updated by: Medical University of Lodz

Genetic Assessment of the Patients With Metabolic Syndrome in Polish Population

Metabolic syndrome is a combination of medical disorders that increase the risk of developing cardiovascular disease and diabetes. The exact mechanisms of the complex pathways of metabolic syndrome are not yet completely known. The pathophysiology is extremely complex and has been only partially elucidated. Most patients are older, obese, sedentary, and have a degree of insulin resistance. Stress can also be a contributing factor. The most important factors are:

weight, genetics, aging, sedentary lifestyle,excess caloric intake. In our study we will assess the role of some polymorphisms in the pathology of metabolic syndrome.

Study Overview

Status

Unknown

Conditions

Detailed Description

Eligibility criteria to the study:

  • patients with metabolic syndrome
  • with written consent

Study Type

Observational

Enrollment (Anticipated)

300

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Lodz, Poland
        • Department of medical biotechnology Medical University of Lodz

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Probability Sample

Study Population

Patients with metabolic syndrome

Description

Inclusion Criteria:

  • patients with metabolic syndrome according to IDF,AHA and NHLBI 2009

Exclusion Criteria:

  • diabetes type 1
  • cancer
  • not consent
  • steroid therapy
  • alcohol or drug abuse
  • chronic inflammatory disease
  • pregnancy or lactation
  • severe hypothyroidism
  • immunosuppressive treatment
  • operation or severe injury during the last month

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
control group
healthy volunteers
Metabolic group
Patients with metabolic syndrome

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Study Chair: Tadeusz Pietrucha, prof., Department of medical biotechnology

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2010

Primary Completion (Anticipated)

August 1, 2011

Study Completion (Anticipated)

January 1, 2015

Study Registration Dates

First Submitted

December 28, 2010

First Submitted That Met QC Criteria

December 30, 2010

First Posted (Estimate)

December 31, 2010

Study Record Updates

Last Update Posted (Estimate)

July 22, 2011

Last Update Submitted That Met QC Criteria

July 20, 2011

Last Verified

December 1, 2010

More Information

Terms related to this study

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Metabolic Syndrome

3
Subscribe